• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

    4.370 -1.510 (-25.68%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,492,570
    Open 5.950
    Bid (Size) 4.450 (200)
    Ask (Size) 4.480 (500)
    Prev. Close 5.880
    Today's Range 4.252 - 5.960
    52wk Range 5.005 - 19.14
    Shares Outstanding 101,102,152
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    Unusual volume stocks are being observed in Tuesday's session. ↗
    Via Chartmill

    Performance

    YTD
    -75.4%
    -75.4%
    1 Month
    -75.7%
    -75.7%
    3 Month
    -70.9%
    -70.9%
    6 Month
    -53.0%
    -53.0%
    1 Year
    -73.0%
    -73.0%

    More News

    Read More
    Keep an eye on the top gainers and losers in Monday's session. ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ ↗
    Via Stocktwits
    Gapping stocks in Monday's session ↗
    Via Chartmill
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
    Via Benzinga
    News headline image
    Atara Biotherapeutics Announces Changes to Its Board of Directors
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    Atara Biotherapeutics Announces Pricing of $16 Million Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
    Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
    What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
    The current price of Atara Biotherapeutics, Inc. - Common Stock is 4.370
    When was Atara Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 01/13/26 04:00 PM ET
    What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 441.82M
    How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
    Atara Biotherapeutics, Inc. - Common Stock has 442M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.